文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新型 18F 标记芳基喹啉衍生物用于阿尔茨海默病 tau 病理的无创成像。

Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.

机构信息

Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan.

出版信息

J Nucl Med. 2013 Aug;54(8):1420-7. doi: 10.2967/jnumed.112.117341. Epub 2013 Jul 15.


DOI:10.2967/jnumed.112.117341
PMID:23857514
Abstract

UNLABELLED: Neurofibrillary tangles in Alzheimer disease (AD) brains are composed of the microtubule-associated protein tau. Noninvasive monitoring of tau protein aggregates in the living brain will provide useful information regarding tau pathophysiology in AD. However, no PET probes are currently available for selective detection of tau pathology in AD. We have previously reported (18)F-labeled THK-523 ((18)F-6-(2-fluoroethoxy)-2-(4-aminophenyl)quinoline) as a tau imaging radiotracer candidate for PET. After compound optimization, we developed novel (18)F-labeled arylquinoline derivatives, (18)F-THK-5105 and (18)F-THK-5117, for use as tau imaging PET tracers. METHODS: (18)F-labeled compounds were prepared from the corresponding tosylated precursors. The binding affinity of compounds to synthetic tau aggregates and tau-rich AD brain homogenates was determined by saturation and competition binding assays. The binding selectivity of compounds to tau pathology was evaluated by autoradiography of AD brain sections. The pharmacokinetics of compounds were assessed in biodistribution studies in normal mice. A 14-d toxicity study with intravenous administration of compounds was performed using rats and mice. RESULTS: In vitro binding assays demonstrated higher binding affinity of THK-5105 and THK-5117 than THK-523 to tau protein aggregates and tau-rich AD brain homogenates. Autoradiographic analyses of AD brain sections showed that these radiotracers preferentially bound to neurofibrillary tangles and neuropil threads, which colocalized with Gallyas-positive and immunoreactive tau protein deposits. The distribution of this radiotracer binding in AD brain sections was completely different from that of (11)C-Pittsburgh compound B, showing preferential binding to amyloid plaques. Furthermore, these derivatives demonstrated abundant initial brain uptake and faster clearance in normal mice than (18)F-THK-523 and other reported (18)F-labeled radiotracers. THK-5105 and THK-5117 showed no toxic effects related to the administration of these compounds in mice and rats and no significant binding for various neuroreceptors, ion channels, and transporters at 1-μM concentrations. CONCLUSION: (18)F-labeled THK-5105 and THK-5117 are promising candidates as PET tau imaging radiotracers.

摘要

未加标签:阿尔茨海默病(AD)大脑中的神经原纤维缠结由微管相关蛋白 tau 组成。在活脑中对 tau 蛋白聚集体进行非侵入性监测将为 AD 中的 tau 病理生理学提供有用信息。然而,目前尚无用于选择性检测 AD 中 tau 病理学的 PET 探针。我们之前曾报道过(18)F 标记的 THK-523((18)F-6-(2-氟乙氧基)-2-(4-氨基苯基)喹啉)作为 PET 用 tau 成像放射性示踪剂候选物。在化合物优化后,我们开发了新型(18)F 标记的芳基喹啉衍生物(18)F-THK-5105 和(18)F-THK-5117,用作 tau 成像 PET 示踪剂。 方法:从相应的 tosylated 前体制备(18)F 标记的化合物。通过饱和和竞争结合测定确定化合物与合成的 tau 聚集体和富含 tau 的 AD 脑匀浆的结合亲和力。通过 AD 脑切片的放射自显影评估化合物对 tau 病理学的结合选择性。在正常小鼠的生物分布研究中评估化合物的药代动力学。使用大鼠和小鼠进行了静脉内给药的化合物 14 天毒性研究。 结果:体外结合测定表明,THK-5105 和 THK-5117 与 tau 蛋白聚集体和富含 tau 的 AD 脑匀浆的结合亲和力高于 THK-523。AD 脑切片的放射自显影分析表明,这些放射性示踪剂优先与神经原纤维缠结和神经原纤维缠结结合,与 Gallyas 阳性和免疫反应性 tau 蛋白沉积物共定位。这种放射性示踪剂在 AD 脑切片中的分布与(11)C-Pittsburgh 化合物 B 完全不同,显示出对淀粉样斑块的优先结合。此外,与(18)F-THK-523 和其他报道的(18)F 标记放射性示踪剂相比,这些衍生物在正常小鼠中表现出丰富的初始脑摄取和更快的清除。THK-5105 和 THK-5117 在小鼠和大鼠中未显示与这些化合物给药相关的毒性作用,并且在 1-μM 浓度下对各种神经受体、离子通道和转运体没有明显结合。 结论:(18)F 标记的 THK-5105 和 THK-5117 是有前途的 PET tau 成像放射性示踪剂候选物。

相似文献

[1]
Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.

J Nucl Med. 2013-7-15

[2]
Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease.

J Nucl Med. 2015-12-23

[3]
Preclinical Evaluation of [(18)F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer.

Mol Imaging Biol. 2016-4

[4]
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.

J Nucl Med. 2016-2

[5]
Candidate PET Radioligand Development for Neurofibrillary Tangles: Two Distinct Radioligand Binding Sites Identified in Postmortem Alzheimer's Disease Brain.

ACS Chem Neurosci. 2016-7-20

[6]
Synthesis and evaluation of 2-pyrrolopyridinylquinoline derivatives as selective tau PET tracers for the diagnosis of Alzheimer's disease.

Nucl Med Biol. 2021-2

[7]
Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology.

Eur J Nucl Med Mol Imaging. 2012-10-26

[8]
Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease.

J Neurosci. 2005-11-23

[9]
In Vivo Comparison of Tau Radioligands F-THK-5351 and F-THK-5317.

J Nucl Med. 2017-6

[10]
Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging.

J Labelled Comp Radiopharm. 2014-1

引用本文的文献

[1]
Ligands for Protein Fibrils of Amyloid-β, α-Synuclein, and Tau.

Chem Rev. 2025-6-11

[2]
Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders.

RSC Med Chem. 2024-11-20

[3]
Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases.

Fundam Res. 2022-11-1

[4]
Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer's Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy.

Neurochem Res. 2024-9

[5]
A novel PET probe to selectively image heat shock protein 90α/β isoforms in the brain.

EJNMMI Radiopharm Chem. 2024-3-4

[6]
Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers.

Molecules. 2024-2-4

[7]
Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.

Curr Med Chem. 2024

[8]
Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits.

Int J Mol Sci. 2023-7-6

[9]
Discovery of High-Affinity Amyloid Ligands Using a Ligand-Based Virtual Screening Pipeline.

J Am Chem Soc. 2023-7-26

[10]
Tau positron emission tomography in patients with cognitive impairment and suspected Alzheimer's disease.

Fukushima J Med Sci. 2023-8-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索